Cargando…
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species
The CCR5-specific antibody Leronlimab is being investigated as a novel immunotherapy that can suppress HIV replication with minimal side effects. Here we studied the virological and immunological consequences of Leronlimab in chronically CCR5-tropic HIV-1 infected humans (n = 5) on suppressive antir...
Autores principales: | Chang, Xiao L., Reed, Jason S., Webb, Gabriela M., Wu, Helen L., Le, Jimmy, Bateman, Katherine B., Greene, Justin M., Pessoa, Cleiton, Waytashek, Courtney, Weber, Whitney C., Hwang, Joseph, Fischer, Miranda, Moats, Cassandra, Shiel, Oriene, Bochart, Rachele M., Crank, Hugh, Siess, Don, Giobbi, Travis, Torgerson, Jeffrey, Agnor, Rebecca, Gao, Lina, Dhody, Kush, Lalezari, Jacob P., Bandar, Ivo Sah, Carnate, Alnor M., Pang, Alina S., Corley, Michael J., Kelly, Scott, Pourhassan, Nader, Smedley, Jeremy, Bimber, Benjamin N., Hansen, Scott G., Ndhlovu, Lishomwa C., Sacha, Jonah B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970399/ https://www.ncbi.nlm.nih.gov/pubmed/35358290 http://dx.doi.org/10.1371/journal.ppat.1010396 |
Ejemplares similares
-
Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission
por: Chang, Xiao L., et al.
Publicado: (2021) -
CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab
por: Chang, Xiao L., et al.
Publicado: (2021) -
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab
por: Elneil, Sohier, et al.
Publicado: (2021) -
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab
por: Agresti, Nicholas, et al.
Publicado: (2021) -
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab
por: Yang, Bryant, et al.
Publicado: (2020)